Abstract
Patients with neoplastic diseases are predisposed to develop invasive fungal infections as the result of impairment of host defense, due principally to pharmacological immuno-suppression as the resulting from intensive cytotoxic chemotherapy, ablative radiation therapy, and corticosteroids. Candida spp., Aspergillus spp., and emerging opportunistic fungal pathogens comprise the principal etiological agents of opportunistic mycoses in cancer patients. This paper will briefly review the recent progress in management of invasive fungal infections and the current problems of invasive mycosis, which currently confront patients with neoplastic diseases.
Keywords
Diagnosis Invasive fungal infection Treatment
KJMM
1996 December;1(1):11-23(13). Epub 2016 February 25
Copyright © 1996 by Korean Journal of Medical Mycology
Language
English
Author
Thomas J. Walsh; Infectious Disease Section, Pediatric Branch, Division of Cancer Treatment National Cancer Institute, Bethesda, Maryland, 20892, USA.
Corresponding
Thomas J. Walsh, Infectious Disease Section, Pediatric Branch, Division of Cancer Treatment National Cancer Institute, Bethesda, Maryland, 20892, USA.
Publication history
Acknowledgements
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thomas J. Walsh
Infectious Disease Section, Pediatric Branch, Division of Cancer Treatment National Cancer Institute, Bethesda, Maryland, 20892, USA.
